This post was co-written with Hariharan Ananthakrishnan from Artera.
Artificial intelligence (AI) and machine learning (ML) are transforming cancer diagnosis and treatment, enabling faster and more accurate decisions for patients. One company at the forefront of this transformation is Artera, a precision medicine company developing an AI-powered platform for cancer treatment planning. The U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with nonmetastatic prostate cancer. The ArteraAI Prostate is now recognized as an FDA-regulated software as a medical device (SaMD). In this post, we explore how Artera used Amazon Web Services (AWS) to develop and scale their AI-powered prostate cancer test, accelerating time to results and enabling personalized treatment recommendations for patients.
Customer…
https://aws.amazon.com/blogs/architecture/how-artera-enhances-prostate-cancer-diagnostics-using-aws/
